Physician profile
Roopa Reddy
NPI 1821007709
$13,181.93
in general payments reported to CMS, 2019-2025
47 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,270 · 2020: $1,560 · 2021: $855 · 2022: $1,062 · 2023: $2,340 · 2024: $2,657 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,434.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,337.36 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $1,261.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $831.97 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Novartis Pharmaceuticals Corporation | $745.17 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $744.49 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $729.55 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $728.01 | 2020-2025 | Jardiance |
| Esperion Therapeutics, INC. | $712.55 | 2020-2025 | Nexletol, Nexlizet |
| Merck Sharp & Dohme LLC | $627.65 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $608.24 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $590.77 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $494.93 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $450.19 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $419.85 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.82 | 2019-2025 | Xifaxan |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopa Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.